Vision gene therapy helps blind mice see again

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. 

When the owl swooped, the “blind” mice ran away. This was thanks to a new type of gene therapy to reprogramme cells deep in the eye to sense light.

After treatment, the mice ran for cover when played a video of an approaching owl, just like mice with normal vision. “You could say they were trying to escape, but we don’t know for sure,” says Rob Lucas of the University of Manchester, UK, co-leader of the team that developed and tested the treatment. “What we can say is that they react to the owl in the same way as sighted mice, whereas the untreated mice didn’t do anything.”

This is the team’s best evidence yet that injecting the gene for a pigment that detects light into the eyes of blind mice can help them see real objects again.

This approach aims to treat all types of blindness caused by damaged or missing rods and cones, the eye’s light receptor cells. Most gene therapies for blindness so far have concentrated on replacing faulty genes in rarer, specific forms of inherited blindness, such as Leber congenital amaurosis.

In earlier attempts, mice could only tell objects apart under extremely bright light, so the new finding is crucial. “Our mice could respond in ordinary light, the equivalent of looking at a computer monitor under ordinary office lighting,” says Lucas.

Read full, original post: Gene therapy cures blindness by replacing vision cells in eyes

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Wave Crest Over Red Cross
Viewpoint: Here are the election-inspired Trump administration healthcare policy reversals expected in the coming months
Aerial Sprayer Over Gradient Fields
Farming, food, and chemicals: Post-midterms, the MAHA alliance between Democrats and MAGA Republicans is bruised but not cowed. What comes next?
Supplement Rain Wellness Illustration
Viewpoint: Bedeviled by “toxic inflammation”? How wellness grifters turn this scientific gray zone into a supplement jackpot
Teal Hexagon Technology Icons
4 key ways the Blue Wave will upend science policy
Confident Doctor in Clinical Setting
More than 80% of ‘pro-science’ candidates were swept into office. Will they have a policy impact?
Stacked Protest Signs on Concrete Ledge
Voters hate AI data centers, yet they are crucial to establishing a critical technology. So what’s next?
Microscopic IVF Egg Injection
With technical barriers to human embryo editing falling, ethical concerns escalate
Democratic Donkey Plowing at Sunset
Viewpoint: Democratic tsunami: As the red tide recedes, here are the most likely shifts in food and agricultural policy
Screenshot-2026-11-05-at-1.20.54-PM
$7.35 billion PFAS settlement: 3M to pay people who blame health problems on ‘forever chemicals’ phased out of firefighting foam for more than 20 years
Protect-Womens-Sports-at-the-Capitol
Blue, purple and red states passed or reaffirmed bans on trans females competing in women’s sports
Prescription Capsules Scattered on Twenty-Dollar Bills
Facts & Fallacies podcast: America's health care system is broken. A doctor explains how to fix it, Part 2
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.